Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Varsha TulpuleGareth J MorrisonMary FalconeDavid I QuinnAmir GoldkornPublished in: Current oncology reports (2022)
To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
Keyphrases
- prostate cancer
- circulating tumor
- squamous cell carcinoma
- circulating tumor cells
- small cell lung cancer
- radical prostatectomy
- minimally invasive
- single cell
- ultrasound guided
- ionic liquid
- dna damage
- stem cells
- dna repair
- risk assessment
- mesenchymal stem cells
- cancer therapy
- climate change
- replacement therapy
- free survival